Project description:Interventions: general anesthesia:epidural blockade ;epidural combined with general group :epidural blockade combined with general Primary outcome(s): serum vascular endothelial growth factor Study Design: Randomized parallel controlled trial

| 2674400 | ecrin-mdr-crc

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Project description:This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or metastatic colorectal cancer receiving first-line treatment with bevacizumab and either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI). This study will also investigate the effect of adding pegfilgrastim to bevacizumab and either FOLFOX or FOLFIRI by evaluating overall survival, progression-free survival, and overall response rate in each arm at regular intervals over a maximum of 60 months follow-up.

| 2073020 | ecrin-mdr-crc

Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.

Project description: Not available

| S-EPMC3883264 | biostudies-literature

Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.

Project description: Not available

| S-EPMC1576298 | biostudies-literature

Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.

Project description: Not available

| S-EPMC2845904 | biostudies-other

Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.

Project description: Not available